Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Williams WP 3rd, McLin DE 3rd, Dressman MA, Neubauer DN
Cost and Affordability This is where many patients start weighing the pros and cons
10.1161/CIRCULATIONAHA.108.816736 153
research-grade peptides are not evaluated for clinical efficacy or safety in human use [11]
Nat Commun 10(1):3998 Mahesh N et al (2022) Carbon-based adsorbents as proficient tools for the removal of heavy metals from aqueous solution: a state of art-review emphasizing recent progress and prospects
This hegemony is about to be permanently disrupted by a new mass market, chronic disease area, which unusually is seeing very high levels of out of pocket spend- in February 2024, Novo Nordisks CEO noted that in Europe, 80% of Wegovy sales so far were paid for out of pocket by patients- showing, against preconception, that European patients were as willing as Americans to pay for their own obesity medications 5
